vs

Side-by-side financial comparison of PARK OHIO HOLDINGS CORP (PKOH) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

PARK OHIO HOLDINGS CORP is the larger business by last-quarter revenue ($395.0M vs $207.3M, roughly 1.9× Ultragenyx Pharmaceutical Inc.). PARK OHIO HOLDINGS CORP runs the higher net margin — 0.3% vs -62.0%, a 62.3% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 1.7%). PARK OHIO HOLDINGS CORP produced more free cash flow last quarter ($36.0M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs -2.7%).

The Park National Bank is the lead bank in the $9.9 billion Park National Corporation serving Ohio, Northern Kentucky, and the Carolinas. The bank has three affiliate financial institutions, including Guardian Finance Company, Scope Aircraft Leasing, and SE Property Holdings, LLC. Park National Bank is headquartered in Newark, Ohio.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

PKOH vs RARE — Head-to-Head

Bigger by revenue
PKOH
PKOH
1.9× larger
PKOH
$395.0M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+24.2% gap
RARE
25.9%
1.7%
PKOH
Higher net margin
PKOH
PKOH
62.3% more per $
PKOH
0.3%
-62.0%
RARE
More free cash flow
PKOH
PKOH
$136.8M more FCF
PKOH
$36.0M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
-2.7%
PKOH

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PKOH
PKOH
RARE
RARE
Revenue
$395.0M
$207.3M
Net Profit
$1.0M
$-128.6M
Gross Margin
17.3%
Operating Margin
2.5%
-54.7%
Net Margin
0.3%
-62.0%
Revenue YoY
1.7%
25.9%
Net Profit YoY
100.0%
3.5%
EPS (diluted)
$0.06
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PKOH
PKOH
RARE
RARE
Q4 25
$395.0M
$207.3M
Q3 25
$398.6M
$159.9M
Q2 25
$400.1M
$166.5M
Q1 25
$405.4M
$139.3M
Q4 24
$388.4M
$164.6M
Q3 24
$417.6M
$139.5M
Q2 24
$432.6M
$147.0M
Q1 24
$417.6M
$108.8M
Net Profit
PKOH
PKOH
RARE
RARE
Q4 25
$1.0M
$-128.6M
Q3 25
$5.3M
$-180.4M
Q2 25
$9.2M
$-115.0M
Q1 25
$8.3M
$-151.1M
Q4 24
$500.0K
$-133.2M
Q3 24
$9.8M
$-133.5M
Q2 24
$11.9M
$-131.6M
Q1 24
$9.6M
$-170.7M
Gross Margin
PKOH
PKOH
RARE
RARE
Q4 25
17.3%
Q3 25
16.7%
Q2 25
17.0%
Q1 25
16.8%
Q4 24
16.6%
Q3 24
17.3%
Q2 24
16.9%
Q1 24
17.1%
Operating Margin
PKOH
PKOH
RARE
RARE
Q4 25
2.5%
-54.7%
Q3 25
4.3%
-106.9%
Q2 25
5.0%
-64.8%
Q1 25
4.7%
-102.6%
Q4 24
3.7%
-74.3%
Q3 24
5.7%
-94.6%
Q2 24
5.7%
-79.1%
Q1 24
5.7%
-151.9%
Net Margin
PKOH
PKOH
RARE
RARE
Q4 25
0.3%
-62.0%
Q3 25
1.3%
-112.8%
Q2 25
2.3%
-69.0%
Q1 25
2.0%
-108.5%
Q4 24
0.1%
-80.9%
Q3 24
2.3%
-95.7%
Q2 24
2.8%
-89.5%
Q1 24
2.3%
-156.8%
EPS (diluted)
PKOH
PKOH
RARE
RARE
Q4 25
$0.06
$-1.28
Q3 25
$0.38
$-1.81
Q2 25
$0.66
$-1.17
Q1 25
$0.60
$-1.57
Q4 24
$0.00
$-1.34
Q3 24
$0.73
$-1.40
Q2 24
$0.92
$-1.52
Q1 24
$0.75
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PKOH
PKOH
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$44.8M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$380.9M
$-80.0M
Total Assets
$1.4B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PKOH
PKOH
RARE
RARE
Q4 25
$44.8M
$421.0M
Q3 25
$50.8M
$202.5M
Q2 25
$45.6M
$176.3M
Q1 25
$54.5M
$127.1M
Q4 24
$53.1M
$174.0M
Q3 24
$59.5M
$150.6M
Q2 24
$59.9M
$480.7M
Q1 24
$61.6M
$112.3M
Stockholders' Equity
PKOH
PKOH
RARE
RARE
Q4 25
$380.9M
$-80.0M
Q3 25
$374.8M
$9.2M
Q2 25
$371.1M
$151.3M
Q1 25
$349.2M
$144.2M
Q4 24
$330.8M
$255.0M
Q3 24
$335.9M
$346.8M
Q2 24
$293.8M
$432.4M
Q1 24
$288.5M
$140.3M
Total Assets
PKOH
PKOH
RARE
RARE
Q4 25
$1.4B
$1.5B
Q3 25
$1.4B
$1.2B
Q2 25
$1.4B
$1.3B
Q1 25
$1.4B
$1.3B
Q4 24
$1.4B
$1.5B
Q3 24
$1.4B
$1.5B
Q2 24
$1.4B
$1.6B
Q1 24
$1.4B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PKOH
PKOH
RARE
RARE
Operating Cash FlowLast quarter
$48.7M
$-99.8M
Free Cash FlowOCF − Capex
$36.0M
$-100.8M
FCF MarginFCF / Revenue
9.1%
-48.6%
Capex IntensityCapex / Revenue
3.2%
0.5%
Cash ConversionOCF / Net Profit
48.70×
TTM Free Cash FlowTrailing 4 quarters
$2.0M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PKOH
PKOH
RARE
RARE
Q4 25
$48.7M
$-99.8M
Q3 25
$17.3M
$-91.4M
Q2 25
$-13.7M
$-108.3M
Q1 25
$-10.0M
$-166.5M
Q4 24
$26.4M
$-79.3M
Q3 24
$9.0M
$-67.0M
Q2 24
$-2.7M
$-77.0M
Q1 24
$2.3M
$-190.7M
Free Cash Flow
PKOH
PKOH
RARE
RARE
Q4 25
$36.0M
$-100.8M
Q3 25
$6.6M
$-92.7M
Q2 25
$-21.1M
$-110.7M
Q1 25
$-19.5M
$-167.8M
Q4 24
$17.3M
$-79.5M
Q3 24
$-100.0K
$-68.6M
Q2 24
$-10.1M
$-79.0M
Q1 24
$-3.5M
$-193.9M
FCF Margin
PKOH
PKOH
RARE
RARE
Q4 25
9.1%
-48.6%
Q3 25
1.7%
-58.0%
Q2 25
-5.3%
-66.5%
Q1 25
-4.8%
-120.5%
Q4 24
4.5%
-48.3%
Q3 24
-0.0%
-49.2%
Q2 24
-2.3%
-53.7%
Q1 24
-0.8%
-178.2%
Capex Intensity
PKOH
PKOH
RARE
RARE
Q4 25
3.2%
0.5%
Q3 25
2.7%
0.8%
Q2 25
1.8%
1.5%
Q1 25
2.3%
1.0%
Q4 24
2.3%
0.1%
Q3 24
2.2%
1.2%
Q2 24
1.7%
1.4%
Q1 24
1.4%
3.0%
Cash Conversion
PKOH
PKOH
RARE
RARE
Q4 25
48.70×
Q3 25
3.26×
Q2 25
-1.49×
Q1 25
-1.20×
Q4 24
52.80×
Q3 24
0.92×
Q2 24
-0.23×
Q1 24
0.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PKOH
PKOH

Supply Technologies Product$164.6M42%
Engineered Products$116.3M29%
Fuel Rubber And Plastic Products$91.6M23%
Engineered Specialty Products$22.5M6%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons